4DMedical And 2 Australian Growth Stocks To Watch

AI related investment is pulling global trade forecasts higher, with the World Trade Organization now expecting stronger goods growth over the next few years as spending on chips and data centres builds. That ripple effect reaches Australian high potential growth stocks, where analysts see solid earnings expansion from companies on strong financial footing. This article highlights three of the strongest candidates from that group.

The stocks below are just a sample, with the wider screen surfacing 91 more companies that analysts expect to combine strong earnings potential with balance sheets that can reasonably support that growth profile. To see the full list and quickly sort through the healthiest high growth prospects, head straight into the Healthy high growth potential screener.

4DMedical (ASX:4DX)

Overview: 4DMedical develops non invasive lung imaging software and scanners such as XV LVAS and CT:VQ that quantify lung function for screening and drug research.

Operations: The business generates about A$7 million from lung function analysis technology, with roughly A$7 million sourced primarily from the United States and a small amount from Australia.

Market Cap: A$2.4b

4DMedical fits the Healthy high growth potential theme through its focus on quantitative lung imaging, where its software platform is being plugged directly into lung screening programs and pulmonary drug studies with large healthcare and pharmaceutical partners.

"Partnership with Philips promised a $10Million USD minimum order commitment contract over the next 2 years starting December 2025 (over 2026 and 2027). Philips has added 4DMedicals CT:VQ technology as an official product on their catalog in North America."

The real swing factor is how one unresolved pressure on future scan volumes and pricing power filters through to margins and long-run earnings quality.

That pressure point sits at the centre of the real debate, and the full narrative for 4DMedical maps how volume, pricing and capital needs could still align for 4DMedical’s long run earnings story.

Neuren Pharmaceuticals (ASX:NEU)

Overview: Neuren Pharmaceuticals develops and commercializes therapies like DAYBUE and NNZ-2591 for rare neurological disorders, targeting high medical-need patients globally.

Operations: Neuren currently generates about A$70 million from commercial products, with all reported revenue coming from the United States market.

Market Cap: A$2.6b

Neuren Pharmaceuticals fits the Healthy high growth potential theme through DAYBUE, a recently commercialized Rett syndrome treatment that anchors its clearest near-term earnings pathway.

"The expectation of increased diagnosed population and patient uptake of DAYBUE in the U.S. indicates potential revenue growth with more patients getting access to the drug."

What happens to future earnings and valuation depends heavily on how one unseen pressure on cash profitability and funding costs evolves from here.

That unseen pressure is exactly where the opportunity and risk start to decouple. The full narrative for Neuren Pharmaceuticals shows how Neuren Pharmaceuticals’ growth story could still accelerate from here.

Netwealth Group (ASX:NWL)

Overview: Netwealth Group runs an Australian wealth platform that hosts superannuation, managed accounts and investment wraps, earning ongoing administration and advice related fees.

Operations: Netwealth Group generates about A$390 million from platform operations in Australia, anchored in superannuation and investment administration services.

Market Cap: A$4.2b

Netwealth Group matters for the Healthy high growth potential theme because its super and investment platform is built around recurring fee income that can scale as more advisers and clients move assets on platform.

"Netwealth's continued investment in best-in-class digital experience, platform functionality, and data analytics aligns with the ongoing digitisation of financial services and increasing regulatory focus on transparency, which may position the company to capture greater adviser and client net inflows, bolster revenue growth, and strengthen platform stickiness."

What happens to future earnings power depends on how pressure on profitability and fee levels shifts as those platform inflows build.

As those fee and margin pressures play out, the full narrative for Netwealth Group pulls together how Netwealth Group's inflows, pricing power and risks could be quietly accelerating the story.

Seeking Fresh Alternatives Beyond These Picks?

Fresh ideas move first. By the time momentum is obvious, the easy entry points are already dropping away. Scan these focused shortlists before the crowd and get in early.

• Target reliable income streams by reviewing the curated 5 dividend fortresses that focus on payouts, which may help anchor your portfolio when growth stories take a breather.
• Ride structural demand for secure infrastructure by assessing the hand picked 43 power grid technology and infrastructure stocks that connect directly to long term grid upgrades and electrification themes.
• Position ahead of commodity sentiment swings by scanning the focused 35 elite gold producer stocks that concentrate on producers with direct exposure to the gold price.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com